Legend Biotech Corporation to Present New Data on Carvykti for Patients with Multiple Myeloma At 2025 Asco and Eha Annual Meeting

Published: 2025-05-23 07:21:21 ET LEGN

Published on 05/23/2025 at 07:21

Legend Biotech Corporation announced that new data from the CARTITUDE Clinical Development Program evaluating CARVYKTI®? (ciltacabtagene autoleucel; cilta-cel) for patients with multiple myeloma will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2025 European Hematology Association's ("EHA") Congress. This announcement has been issued in the English language with a separate Chinese language translation.

If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail. Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.